Development and evaluation of a new protocol for the management of immediate hypersensitivity reactions in an oncology outpatient department.

IF 0.8

Bulletin du cancer Pub Date : 2025-07-07 DOI:10.1016/j.bulcan.2025.03.020

Pierre-Yves Cren, Géraldine Rosier, Nicolas Penel, Diane Pannier, Nathalie Dereumaux, Capucine Aelbrecht-Meurisse, Geoffrey Strobbe, Diane Pelletier de Chambure

{"title":"Development and evaluation of a new protocol for the management of immediate hypersensitivity reactions in an oncology outpatient department.","authors":"Pierre-Yves Cren, Géraldine Rosier, Nicolas Penel, Diane Pannier, Nathalie Dereumaux, Capucine Aelbrecht-Meurisse, Geoffrey Strobbe, Diane Pelletier de Chambure","doi":"10.1016/j.bulcan.2025.03.020","DOIUrl":null,"url":null,"abstract":"Introduction: Management of immediate hypersensitivity reactions (HSRs) is an everyday practice issue in oncology.Objective: Our primary objective aimed to harmonize the management of HSRs. The second aim was to evaluate the implementation of this new protocol and to describe HSRs in real life settings.Methods: First, we held several multidisciplinary meetings to develop an internal consensus. Then, we conducted a prospective assessment.Results: First, this work led to a consensus, resulting in new management guidelines. Second, we identified 25 HSRs involving 23 patients (we treat about 100 patients daily, five days a week). On average, a reaction occurred every 9.8 days. According to Brown's classification, our observations included 9 grade 3 HSRs (36%), 9 grade 2 HSRs (36%), and 7 grade 1 HSRs (28%). Most frequent treatments involved in grade 3 HSRs were: Paclitaxel 3 cases (33%), Carboplatin 3 cases (33%) and Cetuximab 2 cases (22%). Following HSR, we observed a change in the planned anti-cancer treatment strategy in 76% of cases.Conclusion: Our work has standardized the management of HSRs in our cancer hospital. It also allows for close monitoring of HSRs, enabling us to understand them more clearly.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin du cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.bulcan.2025.03.020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Management of immediate hypersensitivity reactions (HSRs) is an everyday practice issue in oncology.

Objective: Our primary objective aimed to harmonize the management of HSRs. The second aim was to evaluate the implementation of this new protocol and to describe HSRs in real life settings.

Methods: First, we held several multidisciplinary meetings to develop an internal consensus. Then, we conducted a prospective assessment.

Results: First, this work led to a consensus, resulting in new management guidelines. Second, we identified 25 HSRs involving 23 patients (we treat about 100 patients daily, five days a week). On average, a reaction occurred every 9.8 days. According to Brown's classification, our observations included 9 grade 3 HSRs (36%), 9 grade 2 HSRs (36%), and 7 grade 1 HSRs (28%). Most frequent treatments involved in grade 3 HSRs were: Paclitaxel 3 cases (33%), Carboplatin 3 cases (33%) and Cetuximab 2 cases (22%). Following HSR, we observed a change in the planned anti-cancer treatment strategy in 76% of cases.

Conclusion: Our work has standardized the management of HSRs in our cancer hospital. It also allows for close monitoring of HSRs, enabling us to understand them more clearly.

查看原文本刊更多论文

制定和评估一个新的方案，以管理肿瘤门诊部的即时过敏反应。

简介：即时超敏反应（HSRs）的管理是肿瘤学的日常实践问题。目的：我们的主要目标是协调hsr的管理。第二个目的是评估这个新方案的实施，并描述现实生活中的高铁。方法：首先，我们召开了几次多学科会议，以形成内部共识。然后，我们进行了前瞻性评估。结果：首先，这项工作导致了共识，产生了新的管理指南。其次，我们确定了涉及23例患者的25例HSRs（我们每天治疗约100例患者，每周5天）。平均每9.8天发生一次反应。根据Brown的分类，我们观察到9例3级hsr(36%)， 9例2级hsr（36%）和7例1级hsr（28%）。3级HSRs最常见的治疗是：紫杉醇3例（33%），卡铂3例（33%）和西妥昔单抗2例（22%）。在高铁治疗后，我们观察到76%的病例计划的抗癌治疗策略发生了变化。结论：我们的工作规范了肿瘤医院hsr的管理。它还允许对高铁进行密切监测，使我们能够更清楚地了解它们。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bulletin du cancer

自引率

0.00%

发文量